Hodgkin's disease in children: treatment results with MOPP and low-dose, extended-field irradiation.
Combined therapy with MOPP and extended-field irradiation for all children with Hodgkin's disease (except those with favorable clinical stage [CS] 1) was effective in disease control. Overall 5-year survival and relapse-free survival rates were 92% and 82%, respectively. Only one of 27 CS 2 and 3 patients has relapsed (median followup, 4.3 years). Two patients in complete remission died of viral infection. The cost-benefit ratio for such treatment remains to be determined. Morbidity was decreased by the omission of staging laparotomy with splenectomy and by reduction in radiation dose and to a lesser extent volume, but it was increased by the addition of MOPP. In such combined treatment, the smallest number of cycles of MOPP, the lowest radiation dose, and the smallest radiation volume that may be used without loss of treatment effectiveness remain to be determined.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002648:Child; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D008466:Mechlorethamine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone